New therapeutics in systemic lupus erythematosus

Current Opinion in Rheumatology

Volumn 25, Issue 3, 2013, Pages 297-303

  Paz, Ziv ^a   Tsokos, George C ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

biological agents; small molecules; systemic lupus erythematosus

Indexed keywords

ABATACEPT; ACETYLCYSTEINE; AFELIMOMAB; AGS 009; AMG 557; AMG 811; ARSENIC TRIOXIDE; BELIMUMAB; BLISIBIMOD; BORTEZOMIB; CARFILZOMIB; CDP 7657; CPD 7657; DELANZOMIB; EPRATUZUMAB; FORIGERIMOD; IMMUNOLOGIC AGENT; LAQUINIMOD; MEDI 546; N [2 [[N [3 (4 CHLOROPHENYL) 2 PROPENYL] N METHYLAMINO]METHYL]PHENYL] N (2 HYDROXYETHYL) 4 METHOXYBENZENESULFONAMIDE; OCRELIZUMAB; OMALIZUMAB; ONX 0914; RAPAMYCIN; RITUXIMAB; RONTALIZUMAB; SBI 087; SIRUKUMAB; TABALUMAB; TAMIBAROTENE; UNCLASSIFIED DRUG;

DISEASE ACTIVITY; DRUG APPROVAL; DRUG EFFICACY; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT RESPONSE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 84875876283     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32835fd682     Document Type: Review

References (51)

1. Thatayatikom A, White AJ. Rituximab: a promising therapy in systemic lupus erythematosus. Autoimmun Rev 2006; 5:18-24.
2. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-toseverely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62:222-233.
3. Fernández-Nebro A, de la Fuente JL, Carreño L, et al. Multicenterlongitudinal study of B-lymphocyte depletion in refractory systemic lupuserythematosus: the LESIMAB study. Lupus 2012; 21:1063-1076.
4. D́az-Lagares C, Croca S, Sangle S, et al., UK-BIOGEAS Registry. Efficacy of rituximab in 164 patients with biopsy-proven lupusnephritis: pooled data from European cohorts. Autoimmun Rev 2012; 11:357-364.
5. Rovin BH, Furie R, Latinis K, et al., LUNAR Investigator Group. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 2012; 64:1215-1226.
6. Lan L, Han F, Chen JH. Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and meta-analysis. J Zhejiang Univ Sci B 2012; 13:731-744.
7. Petri M, Stohl W, Chatham W, et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008; 58:2453-2459.
8. Lutalo PM, D'Cruz DP. Belimumab for the management of systemic lupus erythematosus. Expert Opin Biol Ther 2012; 12:957-963.
9. Fairfax K, Mackay IR, Mackay F. BAFF/BLyS inhibitors: a new prospect for treatment of systemic lupus erythematosus. Life 2012; 64:595-602.
10. Shum K, Askanase A. Belimumab and the clinical data. Curr Rheumatol Rep 2012; 14:310-317.
11. Navarra SV, Guzmán RM, Gallacher AE, et al., BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377:721-731.
12. Van Vollenhoven R, Zamani O, Wallace DJ, et al. Belimumab, a BLyS-specific inhibitor, reduces disease activity and severe flares in seropositive SLE patients: BLISS-76 study. Ann Rheum Dis 2010; 69 (Suppl 3):74.
13. Manzi S, Sánchez-Guerrero J, Merrill JT, et al., on behalf of the BLISS-52 and BLISS-76 Study Groups. Effects of belimumab, a B lymphocyte stimulatorspecific inhibitor, on disease activity across multipleorgan domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 2012; 71:1833-1838.
14. Stohl W, Hiepe F, Latinis KM, et al., BLISS-52 Study Group; BLISS-76 Study Group. Belimumab reduces autoantibodies, normalizes low complement levels, and reduce select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 2012; 64:2328-2337.
15. Boyce EG, Fusco BE. Belimumab: review of use in systemic lupus erythematosus. Clin Ther 2012; 34:1006-1022.
16. Huard B, Tran NL, Benkhoucha M, et al. Selective APRIL blockade delays systemic lupus erythematosus in mouse. PLoS One 2012; 7:e31837.
17. Jacob CO, Guo S, Jacob N, et al. Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice. Arthritis Rheum 2012; 64:1610-1619.
18. Ng YS, Wardemann H, Chelnis J, et al. Bruton's tyrosine kinase is essential for human B cell tolerance. J Exp Med 2004; 200:927-934.
19. Hutcheson J, Vanarsa K, Bashmakov A, et al. Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murinelupus. Arthritis Res Ther 2012; 14:R243.
20. Brandão M, Damá sio J, Marinho A, et al. Systemic lupus erythematosus, progressive multifocal leuko encephalopathy, and T-CD4\+ lymphopenia. Clin Rev Allergy Immunol 2012; 43:302-307.
21. Rabbani MA, Habib HB, Islam M, et al. Survival analysis and prognostic indicators of systemic lupus erythematosus in Pakistani patients. Lupus 2009; 18:848-855.
22. Montero E, Valdes M, Avellanet J, et al. Chemotherapy induced transient B-cell depletion boosts antibody-forming cells expansion driven by an epidermal growth factor-based cancer vaccine. Vaccine 2009; 27:2230-2239.
23. Crisṕn JC, Kyttaris VC, Terhorst C, Tsokos GC. T cells as therapeutic targets in SLE. Nat Rev Rheumatol 2010; 6:317-325.
24. Tsokos GC. Systemic lupus erythematosus. N Engl J Med 2011; 365:2110-2121.
25. Mok CC. Abatacept for systemic lupus erythematosus: the outlook. Expert Opin Biol Ther 2012; 12:1559-1561.
26. Hoi AY, Littlejohn GO. Abatacept in the treatment of lupus. Expert Opin Biol Ther 2012; 12:1399-1406.
27. Ichinose YT, Juang JC, Crispin K, et al. Suppression of autoimmunity and organ pathology in lupus-pronemice upon inhibition of calcium/ calmodulindependent proteinkinase type IV. Arthritis Rheum 2011; 63:523-529.
28. Koga T, Ichinose K, Mizui M, et al. Calcium/calmodulin-dependent protein kinase IV suppresses IL-2 production andregulatory T cell activity in lupus. J Immunol 2012; 189:3490-3496.
29. Apostolidis SA, Crispin JC, Tsokos GC. IL-17-producing T cells in lupus nephritis. Lupus 2011; 20:120-124.
30. Biswas PS, Bhagat G, Pernis AB. IRF4 and its regulators: evolving insights into the pathogenesis of inflammatory arthritis Immunol Rev 2010; 233:79-96.
31. Stirzaker RA, Biswas PS, Gupta S, et al. Administration of fasudil, a ROCK inhibitor, attenuates disease in lupus-prone NZB/W F1 female mice. Lupus 2012; 21:656-661.
32. Badros A, Goloubeva O, Dalal JS, et al. Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature. Cancer 2007; 110:1042-1049.
33. Seavey MM, Lu LD, Stump KL, et al. Novel, orally active,proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms andglomerulonephritis in two preclinical mouse models of SLE. Int Immunopharmacol 2012; 12:257-270.
34. Ichikawa HT, Conley T, Muchamuel T, et al. Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody secreting cells. Arthritis Rheum 2012; 64:493-503.
35. Gergely P Jr, Grossman C, Niland B, et al. Mitochondrial hyperpolarization and ATP depletion in patients with systemic lupus erythematosus. Arthritis Rheum 2002; 46:175-190.
36. Fernandez DR, Telarico T, Bonilla E, et al. Activation of mammalian target of rapamycin controls the loss of TCR in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation. J Immunol 2009; 182:2063-2073.
37. Shah D, Aggarwal A, Bhatnagar A, et al. Association between T lymphocyte sub-sets apoptosis and peripheral blood mononuclear cells oxidative stress in systemic lupus erythematosus. Free Radic Res 2011; 45:559-567.
38. Warner LM, Adams LM, Sehgal SN. Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus. Arthritis Rheum 1994; 37:289-297.
39. Fernandez D, Bonilla E, Mirza N, et al. Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum 2006; 54:2983-2988.
40. Suwannaroj S, Lagoo A, Keisler D, et al. Antioxidants suppress mortality in the female NZB NZW F1 mouse model of systemic lupus erythematosus (SLE). Lupus 2001; 10:258-265.
41. Lai ZW, Hanczko R, Bonilla E, et al. N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2012; 64:2937-2946.
42. Ye Y, Zhao X, Xie H, et al. Efficacy and safety of statins in the prevention of atherosclerosis in patients with systemic lupus erythematosus: a metaanalysis of randomized controlled trials. Int J Cardiol 2012; S0167-5273(12)01311-1313.
43. Steichen O. A clinically releVant benefit of statins in young patients with systemic lupus erythematosus cannot be excluded: comment on the article by Schanberg et al. Arthritis Rheum 2012; 64:2805; author reply 2805-2806.
44. Schanberg LE, Sandborg C, Barnhart HX, et al., Atherosclerosis Prevention in Pediatric Lupus Erythematosus Investigators. Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum 2012; 64:285-296.
45. Ravelli A. Should children and adolescents with systemic lupus erythematosusbe given statin therapy to prevent early atherosclerosis Arthritis Rheum 2012; 64:33-36.
46. Tu H, Li Q, Xiang S, et al. Dual effects of statins therapy in systemic lupus erythematosus and SLE-related atherosclerosis: the potential role for regulatory T cells. Atherosclerosis 2012; 222:29-33.
47. Casella CB, Seguro LP, Takayama L, et al. Juvenile onset systemic lupus erythematosus: a possible role for vitamin D in disease status and bone health. Lupus 2012; 21:1335-1342.
48. Fragoso TS, Dantas AT, Marques CD, et al. 25-Hydroxyivitamin D3 levels in patients with systemic lupus erythematosus and its association with clinical parameters and laboratory tests. Rev Bras Reumatol 2012; 52:60-65.
49. Monticielo OA, Brenol JC, Chies JA, et al. The role of BsmI and FokI vitamin D receptor gene polymorphisms and serum 25-hydroxyvitamin D in Brazilian patients with systemic lupus erythematosus. Lupus 2012; 21:43-52.
50. Mok CC, Birmingham DJ, Ho LY, et al. Vitamin D deficiency as marker for disease activity and damage in systemic lupus erythematosus: a comparison with antidsDNA and anti-C1q. Lupus 2012; 21:36-42.
51. Wang D, Zhang H, Liang J, et al. Allogeneic mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus: 4 years' experience. Cell Transplant 2012.